Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Carlie Tanner, MD, PhD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentNeurology
    Address4150 Clement Street
    San Francisco CA 94121

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Alcalay RN, Aasly J, Berg D, Bressman S, Brice A, Brockmann K, Chan P, Clark L, Cormier F, Corvol JC, Durr A, Facheris M, Farrer M, Foroud TM, Gasser T, Giladi N, Halter C, Lang A, Langston JW, Marras C, Marti-Masso JF, Ruiz Martinez J, Mejia-Santana H, Mirelman A, Pont-Sunyer C, Orr-Urtreger A, Raymond D, Saunders-Pullman R, Schüle B, Tanner C, Tolosa E, Urkowitz A, Vilas D, Wise A, Marder K. Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. Genet Med. 2014 Aug; 16(8):644-5.
        View in: PubMed
      2. Tanner CM, Goldman SM, Ross GW, Grate SJ. The disease intersection of susceptibility and exposure: Chemical exposures and neurodegenerative disease risk. Alzheimers Dement. 2014 Jun; 10(3 Suppl):S213-25.
        View in: PubMed
      3. Goldman SM, Kamel F, Ross GW, Jewell SA, Marras C, Hoppin JA, Umbach DM, Bhudhikanok GS, Meng C, Korell M, Comyns K, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Sandler DP, Langston JW, Tanner CM. Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord. 2014 May 17.
        View in: PubMed
      4. Achey M, Aldred JL, Aljehani N, Bloem BR, Biglan KM, Chan P, Cubo E, Ray Dorsey E, Goetz CG, Guttman M, Hassan A, Khandhar SM, Mari Z, Spindler M, Tanner CM, van den Haak P, Walker R, Wilkinson JR. The past, present, and future of telemedicine for Parkinson's disease. Mov Disord. 2014 Jun; 29(7):871-83.
        View in: PubMed
      5. Tanner CM, Meng CC, Ravina B, Lang A, Kurlan R, Marek K, Oakes D, Seibyl J, Flagg E, Gauger L, Guest DD, Goetz CG, Kieburtz K, Dieuliis D, Fahn S, Elliott RA, Shoulson I. A practical approach to remote longitudinal follow-up of Parkinson's disease: The FOUND study. Mov Disord. 2014 May; 29(6):743-9.
        View in: PubMed
      6. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella CL, Nance MA, Bressman SB, Scott WK, Tanner CM, Mickel SF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak KE, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Payami H, Molho E, Factor SA, Nutt JG, Serrano C, Arroyo M, Ottman R, Pauciulo MW, Nichols WC, Clark LN, Marder KS. Cognitive and Motor Function in Long-Duration PARKIN-Associated Parkinson Disease. JAMA Neurol. 2014 Jan 1; 71(1):62-7.
        View in: PubMed
      7. Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, Shoulson I. Relationship of mediterranean diet and caloric intake to phenoconversion in huntington disease. JAMA Neurol. 2013 Nov 1; 70(11):1382-8.
        View in: PubMed
      8. Lang AE, Eberly S, Goetz CG, Stebbins G, Oakes D, Marek K, Ravina B, Tanner CM, Shoulson I. Movement Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments. Mov Disord. 2013 Dec; 28(14):1980-6.
        View in: PubMed
      9. Kamel F, Goldman SM, Umbach DM, Chen H, Richardson G, Barber MR, Meng C, Marras C, Korell M, Kasten M, Hoppin JA, Comyns K, Chade A, Blair A, Bhudhikanok GS, Webster Ross G, William Langston J, Sandler DP, Tanner CM. Dietary fat intake, pesticide use, and Parkinson's disease. Parkinsonism Relat Disord. 2014 Jan; 20(1):82-7.
        View in: PubMed
      10. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM. Association of cerebrospinal fluid ß-amyloid 1-42, T-tau, P-tau181, and a-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013 Oct; 70(10):1277-87.
        View in: PubMed
      11. Chen H, Burton EA, Ross GW, Huang X, Savica R, Abbott RD, Ascherio A, Caviness JN, Gao X, Gray KA, Hong JS, Kamel F, Jennings D, Kirshner A, Lawler C, Liu R, Miller GW, Nussbaum R, Peddada SD, Rick AC, Ritz B, Siderowf AD, Tanner CM, Tröster AI, Zhang J. Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications. Environ Health Perspect. 2013 Nov-Dec; 121(11-12):1245-52.
        View in: PubMed
      12. Tanner CM. Alpha-synuclein: one key opens many locks. Mov Disord. 2013 Aug; 28(9):1176-8.
        View in: PubMed
      13. Tanner CM. A second honeymoon for Parkinson's disease? N Engl J Med. 2013 Feb 14; 368(7):675-6.
        View in: PubMed
      14. Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S. Which dyskinesia scale best detects treatment response? Mov Disord. 2013 Mar; 28(3):341-6.
        View in: PubMed
      15. Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord. 2013 Mar; 28(3):380-3.
        View in: PubMed
      16. Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. J Parkinsons Dis. 2013 Jan 1; 3(3):231-9.
        View in: PubMed
      17. Goldman SM, Kamel F, Ross GW, Bhudhikanok GS, Hoppin JA, Korell M, Marras C, Meng C, Umbach DM, Kasten M, Chade AR, Comyns K, Richards MB, Sandler DP, Blair A, Langston JW, Tanner CM. Genetic modification of the association of paraquat and Parkinson's disease. Mov Disord. 2012 Nov; 27(13):1652-8.
        View in: PubMed
      18. Ross GW, Duda JE, Abbott RD, Pellizzari E, Petrovitch H, Miller DB, O'Callaghan JP, Tanner CM, Noorigian JV, Masaki K, Launer L, White LR. Brain organochlorines and Lewy pathology: the Honolulu-Asia Aging Study. Mov Disord. 2012 Sep 15; 27(11):1418-24.
        View in: PubMed
      19. Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord. 2012 Sep 15; 27(11):1392-7.
        View in: PubMed
      20. Wang C, Cai Y, Zheng Z, Tang BS, Xu Y, Wang T, Ma J, Chen SD, Langston JW, Tanner CM, Chan P. Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants. Parkinsonism Relat Disord. 2012 Sep; 18(8):958-63.
        View in: PubMed
      21. Kwee LC, Liu Y, Haynes C, Gibson JR, Stone A, Schichman SA, Kamel F, Nelson LM, Topol B, Van den Eeden SK, Tanner CM, Cudkowicz ME, Grasso DL, Lawson R, Muralidhar S, Oddone EZ, Schmidt S, Hauser MA. A high-density genome-wide association screen of sporadic ALS in US veterans. PLoS One. 2012; 7(3):e32768.
        View in: PubMed
      22. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang M-, Rosado L, Orbe Reilly M, Ruiz D, Ross B, Verbitsky M, Kisselev S, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Payami H, Molho E, Factor S, Ottman R, Clark LN, Marder K. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012 May 1; 78(18):1434-40.
        View in: PubMed
      23. Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol. 2012 Mar; 71(3):370-84.
        View in: PubMed
      24. Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, Umbach D, Marras C, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Meng C, Korell M, Roucoux DF, Hoppin JA, Sandler DP, Langston JW, Tanner CM. Head injury, a-synuclein Rep1, and Parkinson's disease. Ann Neurol. 2012 Jan; 71(1):40-8.
        View in: PubMed
      25. Ross GW, Abbott RD, Petrovitch H, Tanner CM, White LR. Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience. Parkinsonism Relat Disord. 2012 Jan; 18 Suppl 1:S199-202.
        View in: PubMed
      26. Srivastava A, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Caccappolo E, Comella C, Colcher A, Siderowf A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Alcalay RN, Ross B, Orbe Reilly M, Rezak M, Novak K, Friedman JH, Pfeiffer RD, Marsh L, Hiner B, Merle D, Ottman R, Clark LN, Marder K. The relation between depression and parkin genotype: the CORE-PD study. Parkinsonism Relat Disord. 2011 Dec; 17(10):740-4.
        View in: PubMed
      27. Goldman SM, Quinlan PJ, Ross GW, Marras C, Meng C, Bhudhikanok GS, Comyns K, Korell M, Chade AR, Kasten M, Priestley B, Chou KL, Fernandez HH, Cambi F, Langston JW, Tanner CM. Solvent exposures and Parkinson disease risk in twins. Ann Neurol. 2012 Jun; 71(6):776-84.
        View in: PubMed
      28. Görges R, Kandror T, Kuschnerus S, Zimny M, Pink R, Palmedo H, Hach A, Rau H, Tanner C, Zaplatnikov K, Bockisch A, Freudenberg L. [Scintigraphically "hot" thyroid nodules mainly go hand in hand with a normal TSH]. Nuklearmedizin. 2011; 50(5):179-88.
        View in: PubMed
      29. Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, Francke U, Mountain JL, Goldman SM, Tanner CM, Langston JW, Wojcicki A, Eriksson N. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet. 2011 Jun; 7(6):e1002141.
        View in: PubMed
      30. McGuire V, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, Mayeux R, Ritz B, Ross GW, Petrovitch H, Topol B, Popat RA, Costello S, Manthripragada AD, Southwick A, Myers RM, Nelson LM. Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium. J Neurol Sci. 2011 Aug 15; 307(1-2):22-9.
        View in: PubMed
      31. Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord. 2011 Mar; 26(4):608-13.
        View in: PubMed
      32. Popat RA, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, Mayeux R, Ritz B, Ross GW, Petrovitch H, Topol B, McGuire V, Costello S, Manthripragada AD, Southwick A, Myers RM, Nelson LM. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease. Eur J Neurol. 2011 May; 18(5):756-65.
        View in: PubMed
      33. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect. 2011 Jun; 119(6):866-72.
        View in: PubMed
      34. Alcalay RN, Siderowf A, Ottman R, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Louis E, Ruiz D, Waters C, Fahn S, Cote L, Frucht S, Ford B, Orbe-Reilly M, Ross B, Verbitsky M, Kisselev S, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Rezak M, Novak KE, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Clark LN, Marder K. Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology. 2011 Jan 25; 76(4):319-26.
        View in: PubMed
      35. Caccappolo E, Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Cote LJ, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Siderowf AD, Ross BM, Verbitsky M, Kisselev S, Ottman R, Clark LN, Marder KS. Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study. J Int Neuropsychol Soc. 2011 Jan; 17(1):91-100.
        View in: PubMed
      36. Shino MY, McGuire V, Van Den Eeden SK, Tanner CM, Popat R, Leimpeter A, Bernstein AL, Nelson LM. Familial aggregation of Parkinson's disease in a multiethnic community-based case-control study. Mov Disord. 2010 Nov 15; 25(15):2587-94.
        View in: PubMed
      37. Valappil RA, Black JE, Broderick MJ, Carrillo O, Frenette E, Sullivan SS, Goldman SM, Tanner CM, Langston JW. Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease. Mov Disord. 2010 Oct 30; 25(14):2296-303.
        View in: PubMed
      38. Lo RY, Tanner CM, Van Den Eeden SK, Albers KB, Leimpeter AD, Nelson LM. Comorbid cancer in Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1809-17.
        View in: PubMed
      39. Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1801-8.
        View in: PubMed
      40. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross BM, Verbitsky M, Kisselev S, Louis ED, Comella C, Colcher A, Jennings D, Nance MA, Bressman SB, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Marder K, Clark LN. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol. 2010 Sep; 67(9):1116-22.
        View in: PubMed
      41. Abbott RD, Ross GW, Tanner CM, Andersen JK, Masaki KH, Rodriguez BL, White LR, Petrovitch H. Late-life hemoglobin and the incidence of Parkinson's disease. Neurobiol Aging. 2012 May; 33(5):914-20.
        View in: PubMed
      42. Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). Mov Disord. 2010 Jul 15; 25(9):1190-4.
        View in: PubMed
      43. Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Ford B, Alcalay RN, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Neils GD, Verbitsky M, Kisselev S, Caccappolo E, Ottman R, Clark LN. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol. 2010 Jun; 67(6):731-8.
        View in: PubMed
      44. Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Clark LN, Marder KS, Caccappolo E. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol. 2010 Aug; 32(7):775-9.
        View in: PubMed
      45. Popat RA, Van Den Eeden SK, Tanner CM, Kushida CA, Rama AN, Black JE, Bernstein A, Kasten M, Chade A, Leimpeter A, Cassidy J, McGuire V, Nelson LM. Reliability and validity of two self-administered questionnaires for screening restless legs syndrome in population-based studies. Sleep Med. 2010 Feb; 11(2):154-60.
        View in: PubMed
      46. Tanner CM. Advances in environmental epidemiology. Mov Disord. 2010; 25 Suppl 1:S58-62.
        View in: PubMed
      47. Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder KS. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol. 2009 Dec; 66(12):1517-22.
        View in: PubMed
      48. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009 Dec; 66(12):1460-8.
        View in: PubMed
      49. Lo RY, Tanner CM, Albers KB, Leimpeter AD, Fross RD, Bernstein AL, McGuire V, Quesenberry CP, Nelson LM, Van Den Eeden SK. Clinical features in early Parkinson disease and survival. Arch Neurol. 2009 Nov; 66(11):1353-8.
        View in: PubMed
      50. Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009 Oct 30; 24(14):2081-90.
        View in: PubMed
      51. Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, Bressman S, Deligtisch A, Marras C, Lyons KE, Bhudhikanok GS, Roucoux DF, Meng C, Abbott RD, Langston JW. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol. 2009 Sep; 66(9):1106-13.
        View in: PubMed
      52. Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology. 2009 Aug 4; 73(5):385-92.
        View in: PubMed
      53. Qin Z, Zhang L, Sun F, Fang X, Meng C, Tanner C, Chan P. Health related quality of life in early Parkinson's disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism Relat Disord. 2009 Dec; 15(10):767-71.
        View in: PubMed
      54. Petrovitch H, Abbott RD, Ross GW, Nelson J, Masaki KH, Tanner CM, Launer LJ, White LR. Bowel movement frequency in late-life and substantia nigra neuron density at death. Mov Disord. 2009 Feb 15; 24(3):371-6.
        View in: PubMed
      55. Ascherio A, Tanner CM. Use of antihypertensives and the risk of Parkinson disease. Neurology. 2009 Feb 10; 72(6):578-9.
        View in: PubMed
      56. Ludlow CL, Adler CH, Berke GS, Bielamowicz SA, Blitzer A, Bressman SB, Hallett M, Jinnah HA, Juergens U, Martin SB, Perlmutter JS, Sapienza C, Singleton A, Tanner CM, Woodson GE. Research priorities in spasmodic dysphonia. Otolaryngol Head Neck Surg. 2008 Oct; 139(4):495-505.
        View in: PubMed
      57. Quik M, O'Leary K, Tanner CM. Nicotine and Parkinson's disease: implications for therapy. Mov Disord. 2008 Sep 15; 23(12):1641-52.
        View in: PubMed
      58. Bronstein J, Carvey P, Chen H, Cory-Slechta D, DiMonte D, Duda J, English P, Goldman S, Grate S, Hansen J, Hoppin J, Jewell S, Kamel F, Koroshetz W, Langston JW, Logroscino G, Nelson L, Ravina B, Rocca W, Ross GW, Schettler T, Schwarzschild M, Scott B, Seegal R, Singleton A, Steenland K, Tanner CM, Van Den Eeden S, Weisskopf M. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environ Health Perspect. 2009 Jan; 117(1):117-21.
        View in: PubMed
      59. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE. Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord. 2008 Apr 15; 23(5):653-9; quiz 776.
        View in: PubMed
      60. Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, Launer L, White LR. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol. 2008 Feb; 63(2):167-73.
        View in: PubMed
      61. May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007 Dec; 22(16):2371-7.
        View in: PubMed
      62. Abbott RD, Ross GW, Petrovitch H, Tanner CM, Davis DG, Masaki KH, Launer LJ, Curb JD, White LR. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord. 2007 Aug 15; 22(11):1581-6.
        View in: PubMed
      63. Marras C, Van den Eeden SK, Fross RD, Benedict-Albers KS, Klingman J, Leimpeter AD, Nelson LM, Risch N, Karter AJ, Bernstein AL, Tanner CM. Minimum incidence of primary cervical dystonia in a multiethnic health care population. Neurology. 2007 Aug 14; 69(7):676-80.
        View in: PubMed
      64. Popat RA, Tanner CM, van den Eeden SK, Bernstein AL, Bloch DA, Leimpeter A, McGuire V, Nelson LM. Effect of non-steroidal anti-inflammatory medications on the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007 Jun; 8(3):157-63.
        View in: PubMed
      65. Ozelius LJ, Foroud T, May S, Senthil G, Sandroni P, Low PA, Reich S, Colcher A, Stern MB, Ondo WG, Jankovic J, Huang N, Tanner CM, Novak P, Gilman S, Marshall FJ, Wooten GF, Chelimsky TC, Shults CW. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord. 2007 Mar 15; 22(4):546-9.
        View in: PubMed
      66. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007 Mar 13; 68(11):812-9.
        View in: PubMed
      67. Langston JW, Tanner CM, Schüle B. Parkin gene variations and parkinsonism: association does not imply causation. Ann Neurol. 2007 Jan; 61(1):4-6.
        View in: PubMed
      68. Kasten M, Chade A, Tanner CM. Epidemiology of Parkinson's disease. Handb Clin Neurol. 2007; 83:129-51.
        View in: PubMed
      69. Ross GW, Abbott RD, Petrovitch H, Tanner CM, Davis DG, Nelson J, Markesbery WR, Hardman J, Masaki K, Launer L, White LR. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord. 2006 Dec; 21(12):2062-7.
        View in: PubMed
      70. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007 Jan 30; 68(5):384-6.
        View in: PubMed
      71. Elbaz A, Nelson LM, Payami H, Ioannidis JP, Fiske BK, Annesi G, Carmine Belin A, Factor SA, Ferrarese C, Hadjigeorgiou GM, Higgins DS, Kawakami H, Krüger R, Marder KS, Mayeux RP, Mellick GD, Nutt JG, Ritz B, Samii A, Tanner CM, Van Broeckhoven C, Van Den Eeden SK, Wirdefeldt K, Zabetian CP, Dehem M, Montimurro JS, Southwick A, Myers RM, Trikalinos TA. Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurol. 2006 Nov; 5(11):917-23.
        View in: PubMed
      72. Popat RA, Van Den Eeden SK, Tanner CM, Bernstein AL, Bloch DA, Leimpeter A, McGuire V, Nelson LM. Effect of reproductive factors and postmenopausal hormone use on the risk of amyotrophic lateral sclerosis. Neuroepidemiology. 2006; 27(3):117-21.
        View in: PubMed
      73. Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. Head injury and Parkinson's disease risk in twins. Ann Neurol. 2006 Jul; 60(1):65-72.
        View in: PubMed
      74. Tilley BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, Shannon K, Wooten GF, Tanner CM, Goetz GC. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology. 2006 Mar 14; 66(5):628-33.
        View in: PubMed
      75. Glatt C, Almonte M, Taylor T, Edwards RH, Freimer N, Tanner C. Structural variants in the vesicular monoamine transporter do not contribute to sporadic Parkinson's disease. Mov Disord. 2006 Mar; 21(3):426-7.
        View in: PubMed
      76. Chade AR, Kasten M, Tanner CM. Nongenetic causes of Parkinson's disease. J Neural Transm Suppl. 2006; (70):147-51.
        View in: PubMed
      77. Gilman S, May SJ, Shults CW, Tanner CM, Kukull W, Lee VM, Masliah E, Low P, Sandroni P, Trojanowski JQ, Ozelius L, Foroud T. The North American Multiple System Atrophy Study Group. J Neural Transm. 2005 Dec; 112(12):1687-94.
        View in: PubMed
      78. Abbott RD, Ross GW, White LR, Tanner CM, Masaki KH, Nelson JS, Curb JD, Petrovitch H. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology. 2005 Nov 8; 65(9):1442-6.
        View in: PubMed
      79. Goldman SM, Tanner CM, Olanow CW, Watts RL, Field RD, Langston JW. Occupation and parkinsonism in three movement disorders clinics. Neurology. 2005 Nov 8; 65(9):1430-5.
        View in: PubMed
      80. Tröster AI, Pahwa R, Fields JA, Tanner CM, Lyons KE. Quality of life in Essential Tremor Questionnaire (QUEST): development and initial validation. Parkinsonism Relat Disord. 2005 Sep; 11(6):367-73.
        View in: PubMed
      81. Popat RA, Van Den Eeden SK, Tanner CM, McGuire V, Bernstein AL, Bloch DA, Leimpeter A, Nelson LM. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology. 2005 Aug 9; 65(3):383-90.
        View in: PubMed
      82. Reed T, Plassman BL, Tanner CM, Dick DM, Rinehart SA, Nichols WC. Verification of self-report of zygosity determined via DNA testing in a subset of the NAS-NRC twin registry 40 years later. Twin Res Hum Genet. 2005 Aug; 8(4):362-7.
        View in: PubMed
      83. Marras C, Lang AE, Oakes D, McDermott MP, Kieburtz K, Shoulson I, Tanner CM, Fahn S. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005 Jul 19; 143(2):152-3; author reply 156-8.
        View in: PubMed
      84. Marras C, Goldman S, Smith A, Barney P, Aston D, Comyns K, Korell M, Langston JW, Ross GW, Tanner CM. Smell identification ability in twin pairs discordant for Parkinson's disease. Mov Disord. 2005 Jun; 20(6):687-93.
        View in: PubMed
      85. Park M, Ross GW, Petrovitch H, White LR, Masaki KH, Nelson JS, Tanner CM, Curb JD, Blanchette PL, Abbott RD. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology. 2005 Mar 22; 64(6):1047-51.
        View in: PubMed
      86. Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
        View in: PubMed
      87. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology. 2005 Jan 11; 64(1):87-93.
        View in: PubMed
      88. Guimaraes P, Kieburtz K, Goetz CG, Elm JJ, Palesch YY, Huang P, Ravina B, Tanner CM, Tilley BC. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
        View in: PubMed
      89. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 9; 351(24):2498-508.
        View in: PubMed
      90. Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, Hardman J, Launer L, Masaki K, Tanner CM, White LR. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol. 2004 Oct; 56(4):532-9.
        View in: PubMed
      91. Tanner CM. PD or not PD? That is the question. Neurology. 2003 Jul 8; 61(1):5-6.
        View in: PubMed
      92. Tan LC, Tanner CM, Chen R, Chan P, Farrer M, Hardy J, Langston JW. Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation. Mov Disord. 2003 Jul; 18(7):758-63.
        View in: PubMed
      93. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003 Jun 1; 157(11):1015-22.
        View in: PubMed
      94. Lyons KE, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, Jankovic J, Juncos JL, Koller WC, Ondo WG, Sethi KD, Stern MB, Tanner CM, Tintner R, Watts RL. Benefits and risks of pharmacological treatments for essential tremor. Drug Saf. 2003; 26(7):461-81.
        View in: PubMed
      95. Tanner CM. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol. 2003; 91:133-42.
        View in: PubMed
      96. Petrovitch H, Ross GW, Abbott RD, Sanderson WT, Sharp DS, Tanner CM, Masaki KH, Blanchette PL, Popper JS, Foley D, Launer L, White LR. Plantation work and risk of Parkinson disease in a population-based longitudinal study. Arch Neurol. 2002 Nov; 59(11):1787-92.
        View in: PubMed
      97. Abbott RD, Ross GW, White LR, Nelson JS, Masaki KH, Tanner CM, Curb JD, Blanchette PL, Popper JS, Petrovitch H. Midlife adiposity and the future risk of Parkinson's disease. Neurology. 2002 Oct 8; 59(7):1051-7.
        View in: PubMed
      98. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002 May; 51(5):604-12.
        View in: PubMed
      99. Tanner CM, Goldman SM, Aston DA, Ottman R, Ellenberg J, Mayeux R, Langston JW. Smoking and Parkinson's disease in twins. Neurology. 2002 Feb 26; 58(4):581-8.
        View in: PubMed
      100. Tanner CM, Goldman SM, Lyons KE, Aston DA, Tetrud JW, Welsh MD, Langston JW, Koller WC. Essential tremor in twins: an assessment of genetic vs environmental determinants of etiology. Neurology. 2001 Oct 23; 57(8):1389-91.
        View in: PubMed
      101. Figueroa KP, Chan P, Schöls L, Tanner C, Riess O, Perlman SL, Geschwind DH, Pulst SM. Association of moderate polyglutamine tract expansions in the slow calcium-activated potassium channel type 3 with ataxia. Arch Neurol. 2001 Oct; 58(10):1649-53.
        View in: PubMed
      102. Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D, Forno L, Gwinn-Hardy K, Petrucelli L, Hussey J, Singleton A, Tanner C, Hardy J, Langston JW. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol. 2001 Sep; 50(3):293-300.
        View in: PubMed
      103. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology. 2001 Aug 14; 57(3):456-62.
        View in: PubMed
      104. Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, Tanner C. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology. 2001 Jun 26; 56(12):1712-21.
        View in: PubMed
      105. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, Dubinsky RM, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001 Jun 12; 56(11):1523-8.
        View in: PubMed
      106. Tanner CM, Chamberland J. Latah in Jakarta, Indonesia. Mov Disord. 2001 May; 16(3):526-9.
        View in: PubMed
      107. Sobel N, Thomason ME, Stappen I, Tanner CM, Tetrud JW, Bower JM, Sullivan EV, Gabrieli JD. An impairment in sniffing contributes to the olfactory impairment in Parkinson's disease. Proc Natl Acad Sci U S A. 2001 Mar 27; 98(7):4154-9.
        View in: PubMed
      108. Scahill L, Tanner C, Dure L. The epidemiology of tics and Tourette syndrome in children and adolescents. Adv Neurol. 2001; 85:261-71.
        View in: PubMed
      109. Langston JW, Tanner CM. Selegiline and Parkinson's disease: it's déjà vu-again. Neurology. 2000 Dec 26; 55(12):1770-1.
        View in: PubMed
      110. Tanner CM. Dopamine agonists in early therapy for Parkinson disease: promise and problems. JAMA. 2000 Oct 18; 284(15):1971-3.
        View in: PubMed
      111. Tanner CM, Aston DA. Epidemiology of Parkinson's disease and akinetic syndromes. Curr Opin Neurol. 2000 Aug; 13(4):427-30.
        View in: PubMed
      112. Carragee EJ, Chen Y, Tanner CM, Hayward C, Rossi M, Hagle C. Can discography cause long-term back symptoms in previously asymptomatic subjects? Spine (Phila Pa 1976). 2000 Jul 15; 25(14):1803-8.
        View in: PubMed
      113. Carragee EJ, Tanner CM, Khurana S, Hayward C, Welsh J, Date E, Truong T, Rossi M, Hagle C. The rates of false-positive lumbar discography in select patients without low back symptoms. Spine (Phila Pa 1976). 2000 Jun 1; 25(11):1373-80; discussion 1381.
        View in: PubMed
      114. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000 May 24-31; 283(20):2674-9.
        View in: PubMed
      115. Page WF, Tanner CM. Parkinson's disease and motor-neuron disease in former prisoners-of-war. Lancet. 2000 Mar 4; 355(9206):843.
        View in: PubMed
      116. Togasaki DM, Tanner CM. Epidemiologic aspects. Adv Neurol. 2000; 82:53-9.
        View in: PubMed
      117. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW. Parkinson disease in twins: an etiologic study. JAMA. 1999 Jan 27; 281(4):341-6.
        View in: PubMed
      118. Tanner CM, Ben-Shlomo Y. Epidemiology of Parkinson's disease. Adv Neurol. 1999; 80:153-9.
        View in: PubMed
      119. Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology. 1998 Sep; 51(3):811-4.
        View in: PubMed
      120. Chan P, Jiang X, Forno LS, Di Monte DA, Tanner CM, Langston JW. Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease. Neurology. 1998 Apr; 50(4):1136-7.
        View in: PubMed
      121. Chan P, Tanner CM, Jiang X, Langston JW. Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease. Neurology. 1998 Feb; 50(2):513-4.
        View in: PubMed
      122. Tanner CM, Goldman SM. Epidemiology of Tourette syndrome. Neurol Clin. 1997 May; 15(2):395-402.
        View in: PubMed
      123. Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology. 1997 Apr; 48(4):1070-7.
        View in: PubMed
      124. Shale H, Tanner C. Pharmacological options for the management of dyskinesias. Drugs. 1996 Dec; 52(6):849-60.
        View in: PubMed
      125. Tanner CM. Early intervention in Parkinson's disease: epidemiologic considerations. Ann Epidemiol. 1996 Sep; 6(5):438-41.
        View in: PubMed
      126. Sandy MS, Armstrong M, Tanner CM, Daly AK, Di Monte DA, Langston JW, Idle JR. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology. 1996 Jul; 47(1):225-30.
        View in: PubMed
      127. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin. 1996 May; 14(2):317-35.
        View in: PubMed
      128. Tanner CM, Goldman SM. Epidemiology of movement disorders. Curr Opin Neurol. 1994 Aug; 7(4):340-5.
        View in: PubMed
      129. Tanner CM, Melamed E, Lees AJ. Managing motor fluctuations, dyskinesias, and other adverse effects in Parkinson's disease. Neurology. 1994 Mar; 44(3 Suppl 1):S12-6.
        View in: PubMed
      130. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol. 1993 Nov; 34(5):710-4.
        View in: PubMed
      131. Kurth MC, Tetrud JW, Tanner CM, Irwin I, Stebbins GT, Goetz CG, Langston JW. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology. 1993 Sep; 43(9):1698-703.
        View in: PubMed
      132. Buchman AS, Comella CL, Stebbins GT, Tanner CM, Goetz CG. Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia. Clin Neuropharmacol. 1993 Jun; 16(3):205-10.
        View in: PubMed
      133. Tangney CC, Tanner CM. Vitamin E and PD. Neurology. 1993 Mar; 43(3 Pt 1):634-5.
        View in: PubMed
      134. Wilson RS, Gilley DW, Tanner CM, Goetz CG. Ideational fluency in Parkinson's disease. Brain Cogn. 1992 Nov; 20(2):236-44.
        View in: PubMed
      135. Tanner CM. Occupational and environmental causes of parkinsonism. Occup Med. 1992 Jul-Sep; 7(3):503-13.
        View in: PubMed
      136. Comella CL, Tanner CM, DeFoor-Hill L, Smith C. Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings. Neurology. 1992 Jul; 42(7):1307-10.
        View in: PubMed
      137. Tanner CM. Epidemiology of Parkinson's disease. Neurol Clin. 1992 May; 10(2):317-29.
        View in: PubMed
      138. Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology. 1992 Apr; 42(4):878-82.
        View in: PubMed
      139. Goetz CG, Tanner CM, Stebbins GT, Leipzig G, Carr WC. Adult tics in Gilles de la Tourette's syndrome: description and risk factors. Neurology. 1992 Apr; 42(4):784-8.
        View in: PubMed
      140. Tanner CM. Liver enzyme abnormalities in Parkinson's disease. Geriatrics. 1991 Aug; 46 Suppl 1:60-3.
        View in: PubMed
      141. Tanner CM. Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second look. Neurology. 1991 May; 41(5 Suppl 2):89-91; discussion 92.
        View in: PubMed
      142. Olanow CW, Koller W, Goetz CG, Stebbins GT, Cahill DW, Gauger LL, Morantz R, Penn RD, Tanner CM, Klawans HL, et al. Autologous transplantation of adrenal medulla in Parkinson's disease. 18-month results. Arch Neurol. 1990 Dec; 47(12):1286-9.
        View in: PubMed
      143. Tanner CM, Langston JW. Do environmental toxins cause Parkinson's disease? A critical review. Neurology. 1990 Oct; 40(10 Suppl 3):suppl 17-30; discussion 30-1.
        View in: PubMed
      144. Koller W, Vetere-Overfield B, Gray C, Alexander C, Chin T, Dolezal J, Hassanein R, Tanner C. Environmental risk factors in Parkinson's disease. Neurology. 1990 Aug; 40(8):1218-21.
        View in: PubMed
      145. Goetz CG, Tanner CM, Penn RD, Stebbins GT, Gilley DW, Shannon KM, Klawans HL, Comella CL, Wilson RS, Witt T. Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data. Neurology. 1990 Feb; 40(2):273-6.
        View in: PubMed
      146. Carvey PM, McRae A, Ptak LR, Kao LC, Lo ES, Goetz CG, Tanner CM, Penn RD, Klawans HL. Disappearance of a putative DA-neuron antibody following adrenal medulla transplantation: relationship to a striatal-derived DA neuron trophic factor. Prog Brain Res. 1990; 82:693-7.
        View in: PubMed
      147. Goety CG, Tanner CM, Cohen JA, Thelen JA, Carroll VS, Klawans HL, Fariello RG. L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov Disord. 1990; 5(3):263-5.
        View in: PubMed
      148. Goetz CG, Tanner CM. Gilles de la Tourette's syndrome in twins: clinical and neurochemical data. Mov Disord. 1990; 5(2):173-5.
        View in: PubMed
      149. Goetz CG, Tanner CM, Gilley DW, Klawans HL. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa. Neurology. 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3.
        View in: PubMed
      150. Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 1989 Oct; 12(5):375-83.
        View in: PubMed
      151. Goetz CG, Shannon KM, Tanner CM, Carroll VS, Klawans HL. Agonist substitution in advanced Parkinson's disease. Neurology. 1989 Aug; 39(8):1121-2.
        View in: PubMed
      152. Tanner CM, Chen B, Wang W, Peng M, Liu Z, Liang X, Kao LC, Gilley DW, Goetz CG, Schoenberg BS. Environmental factors and Parkinson's disease: a case-control study in China. Neurology. 1989 May; 39(5):660-4.
        View in: PubMed
      153. Schurman DJ, Bloch DA, Segal MR, Tanner CM. Conventional cemented total hip arthroplasty. Assessment of clinical factors associated with revision for mechanical failure. Clin Orthop Relat Res. 1989 Mar; (240):173-80.
        View in: PubMed
      154. Goetz CG, Olanow CW, Koller WC, Penn RD, Cahill D, Morantz R, Stebbins G, Tanner CM, Klawans HL, Shannon KM. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med. 1989 Feb 9; 320(6):337-41.
        View in: PubMed
      155. Tanner CM. The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci. 1989 Feb; 12(2):49-54.
        View in: PubMed
      156. Goetz CG, Tanner CM, Stebbins GT, Buchman AS. Risk factors for progression in Parkinson's disease. Neurology. 1988 Dec; 38(12):1841-4.
        View in: PubMed
      157. McRae-Degueurce A, Klawans HL, Penn RD, Dahlstrom A, Tanner CM, Goetz CG, Carvey PM. An antibody in the CSF of Parkinson's disease patients disappears following adrenal medulla transplantation. Neurosci Lett. 1988 Nov 22; 94(1-2):192-7.
        View in: PubMed
      158. Sprague SM, Corwin HL, Tanner CM, Wilson RS, Green BJ, Goetz CG. Relationship of aluminum to neurocognitive dysfunction in chronic dialysis patients. Arch Intern Med. 1988 Oct; 148(10):2169-72.
        View in: PubMed
      159. Goetz CG, Tanner CM, Shannon KM, Carroll VS, Klawans HL, Carvey PM, Gilley D. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology. 1988 Jul; 38(7):1143-6.
        View in: PubMed
      160. Penn RD, Goetz CG, Tanner CM, Klawans HL, Shannon KM, Comella CL, Witt TR. The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients. Neurosurgery. 1988 Jun; 22(6 Pt 1):999-1004.
        View in: PubMed
      161. Goetz CG, Penn RD, Tanner CM. Efficacy of cervical cord stimulation in dystonia. Adv Neurol. 1988; 50:645-9.
        View in: PubMed
      162. Klawans HL, Tanner CM, Goetz CG. Epidemiology and pathophysiology of tardive dyskinesias. Adv Neurol. 1988; 49:185-97.
        View in: PubMed
      163. Klawans HL, Tanner CM. Cholinergic pharmacology of blepharospasm with oromandibular dystonia (Meige's syndrome). Adv Neurol. 1988; 49:443-50.
        View in: PubMed
      164. Carvey PM, Hitri A, Goetz CG, Tanner CM, Klawans HL. Concurrent treatment with benztropine and haloperidol attenuates development of behavioral hypersensitivity but not dopamine receptor proliferation. Life Sci. 1988; 42(22):2207-15.
        View in: PubMed
      165. Tanner CM, Wilson RS, Goetz CG, Shannon KM. The predictive value of acute antimuscarinic drugs for the chronic efficacy of antimuscarinic drugs in adults with focal dystonia. Adv Neurol. 1988; 50:557-60.
        View in: PubMed
      166. Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol. 1987 Dec; 10(6):522-6.
        View in: PubMed
      167. Goetz CG, Tanner CM, Wilson RS, Shannon KM. A rating scale for Gilles de la Tourette's syndrome: description, reliability, and validity data. Neurology. 1987 Sep; 37(9):1542-4.
        View in: PubMed
      168. Goetz CG, Tanner CM, Carroll VS, Shannon KM, Klawans HL. Controlled-release Sinemet. Neurology. 1987 Sep; 37(9):1567-8.
        View in: PubMed
      169. Tanner CM, Chen B, Wang WZ, Peng ML, Liu ZL, Liang XL, Kao LC, Gilley DW, Schoenberg BS. Environmental factors in the etiology of Parkinson's disease. Can J Neurol Sci. 1987 Aug; 14(3 Suppl):419-23.
        View in: PubMed
      170. Goetz CG, Tanner CM, Klawans HL, Shannon KM, Carroll VS. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet). Neurology. 1987 May; 37(5):875-8.
        View in: PubMed
      171. Harris M, Nora L, Tanner CM. Neuroleptic malignant syndrome responsive to carbidopa/levodopa: support for a dopaminergic pathogenesis. Clin Neuropharmacol. 1987 Apr; 10(2):186-9.
        View in: PubMed
      172. Goetz CG, Tanner CM, Shannon KM. Progression of Parkinson's disease without levodopa. Neurology. 1987 Apr; 37(4):695-8.
        View in: PubMed
      173. Goetz CG, Tanner CM, Wilson RS, Carroll VS, Como PG, Shannon KM. Clonidine and Gilles de la Tourette's syndrome: double-blind study using objective rating methods. Ann Neurol. 1987 Mar; 21(3):307-10.
        View in: PubMed
      174. Goetz CG, Shannon KM, Carroll VS, Tanner CM, Weingarten R. The autonomic nervous system in Gilles de la Tourette's syndrome. Mov Disord. 1987; 2(2):99-102.
        View in: PubMed
      175. Goetz CG, Wilson RS, Tanner CM, Garron DC. Relationships among pain, depression, and sleep alterations in Parkinson's disease. Adv Neurol. 1987; 45:345-7.
        View in: PubMed
      176. Tanner CM, Goetz CG, Glantz RH, Klawans HL. Pergolide mesylate: four years experience in Parkinson's disease. Adv Neurol. 1987; 45:547-9.
        View in: PubMed
      177. Klawans HL, Carvey PM, Nelson D, Tanner CM, Goetz CG. The effect of thioridazine on haloperidol induced behavioral hypersensitivity. Life Sci. 1986 May 12; 38(19):1707-14.
        View in: PubMed
      178. Carvey PM, Kao LC, Tanner CM, Goetz CG, Klawans HL. The effect of antimuscarinic agents on haloperidol induced behavioral hypersensitivity. Eur J Pharmacol. 1986 Jan 21; 120(2):193-9.
        View in: PubMed
      179. Goetz CG, Lutge W, Tanner CM. Autonomic dysfunction in Parkinson's disease. Neurology. 1986 Jan; 36(1):73-5.
        View in: PubMed
      180. Tanner CM, Klawans HL. Tardive dyskinesia: prevention and treatment. Clin Neuropharmacol. 1986; 9 Suppl 2:S76-84.
        View in: PubMed
      181. Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in Parkinson's disease. Mov Disord. 1986; 1(1):45-9.
        View in: PubMed
      182. Klawans HL, Carvey PM, Tanner CM, Goetz CG. Drug-induced myoclonus. Adv Neurol. 1986; 43:251-64.
        View in: PubMed
      183. Tanner CM, Chhablani R, Goetz CG, Klawans HL. Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease. Neurology. 1985 Jun; 35(6):918-21.
        View in: PubMed
      184. Goetz CG, Tanner CM, Glantz RH, Klawans HL. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology. 1985 May; 35(5):749-51.
        View in: PubMed
      185. Klawans HL, Carvey P, Tanner CM, Goetz CG. The pathophysiology of tardive dyskinesia. J Clin Psychiatry. 1985 Apr; 46(4 Pt 2):38-41.
        View in: PubMed
      186. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology. 1984 Aug; 34(8):1092-4.
        View in: PubMed
      187. Goetz CG, Carvey PM, Tanner CM, Klawans HL. Neuroleptic-induced dopamine hyposensitivity. Life Sci. 1984 Apr 9; 34(15):1475-9.
        View in: PubMed
      188. Goetz CG, Tanner CM, Klawans HL. Fluphenazine and multifocal tic disorders. Arch Neurol. 1984 Mar; 41(3):271-2.
        View in: PubMed
      189. Goetz CG, Tanner CM, Klawans HL. The pharmacology of olivopontocerebellar atrophy. Adv Neurol. 1984; 41:143-8.
        View in: PubMed
      190. Klawans HL, Tanner CM, Barr A. The reversibility of "permanent" tardive dyskinesia. Clin Neuropharmacol. 1984; 7(2):153-9.
        View in: PubMed
      191. Goetz CG, Tanner CM, Glantz R, Klawans HL. Pergolide in Parkinson's disease. Arch Neurol. 1983 Dec; 40(13):785-7.
        View in: PubMed
      192. Tanner CM. Loss of nLC neurons. Neurology. 1983 Apr; 33(4):524.
        View in: PubMed
      193. Nausieda PA, Tanner CM, Klawans HL. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Adv Neurol. 1983; 37:23-32.
        View in: PubMed
      194. Klawans HL, Goetz CG, Tanner CM, Nausieda PA, Weiner WJ. Levodopa-free periods ("drug holidays") in the management of parkinsonism. Adv Neurol. 1983; 37:33-43.
        View in: PubMed
      195. Klawans HL, Tanner CM, Glatt S, Goetz CG. A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson's disease. Adv Neurol. 1983; 37:75-83.
        View in: PubMed
      196. Goetz CG, Tanner CM, Klawans HL. Drug holiday in the management of Parkinson disease. Clin Neuropharmacol. 1982 Dec; 5(4):351-64.
        View in: PubMed
      197. Tanner CM, Goetz CG, Klawans HL. Cholinergic mechanisms in Tourette syndrome. Neurology. 1982 Nov; 32(11):1315-7.
        View in: PubMed
      198. Tanner CM, Goetz CG, Glantz RH, Glatt SL, Klawans HL. Pergolide mesylate and idiopathic Parkinson disease. Neurology. 1982 Oct; 32(10):1175-9.
        View in: PubMed
      199. Tanner CM, Glantz RH, Klawans HL. Meige disease: acute and chronic cholinergic effects. Neurology. 1982 Jul; 32(7):783-5.
        View in: PubMed
      200. Klawans HL, Stein RW, Tanner CM, Goetz CG. A pure parkinsonian syndrome following acute carbon monoxide intoxication. Arch Neurol. 1982 May; 39(5):302-4.
        View in: PubMed
      201. Bergen D, Tanner CM, Wilson R. The electroencephalogram in Tourette syndrome. Ann Neurol. 1982 Apr; 11(4):382-5.
        View in: PubMed
      202. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry. 1982 Apr; 139(4):494-7.
        View in: PubMed
      203. Tanner CM, Klawans HL. Pergolide mesylate: new therapy for Parkinson disease. Ann Intern Med. 1982 Apr; 96(4):522-3.
        View in: PubMed
      204. Klawans HL, Glantz R, Tanner CM, Goetz CG. Primary writing tremor: a selective action tremor. Neurology. 1982 Feb; 32(2):203-6.
        View in: PubMed
      205. Klawans HL, Nausieda PA, Goetz CC, Tanner CM, Weiner WJ. Tourette-like symptoms following chronic neuroleptic therapy. Adv Neurol. 1982; 35:415-8.
        View in: PubMed
      206. Goetz CG, Tanner CM, Klawans HL. Compressive neuropathies in Tourette syndrome. Adv Neurol. 1982; 35:345-7.
        View in: PubMed
      207. Wilson RS, Garron DC, Tanner CM, Klawans HL. Behavior disturbance in children with Tourette syndrome. Adv Neurol. 1982; 35:329-33.
        View in: PubMed
      208. Nausieda PA, Tanner CM, Weiner WJ. Opsoclonic cerebellopathy: A paraneoplastic syndrome responsive to thiamine. Arch Neurol. 1981 Dec; 38(12):780-1.
        View in: PubMed
      209. Goetz CG, Tanner CM, Nausieda PA. Weekly drug holiday in Parkinson disease. Neurology. 1981 Nov; 31(11):1460-2.
        View in: PubMed
      210. Tanner CM, Goetz CG. CPK values in Parkinson's disease. N Engl J Med. 1981 Jun 25; 304(26):1608-9.
        View in: PubMed
      211. Tanner C, Goetz CG, Weiner WJ. Anticholinergics and tardive dyskinesia. Am J Psychiatry. 1980 Nov; 137(11):1470-1.
        View in: PubMed
      Back to TOP